enVVeno Medical Corporation: Positive Long-Term VenoValve First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum
- First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery- No venous ulcer recurrences, relapses of CVI, or safety issues- Improvements in average Reflux
Source: finanznachrichten.de